Core Viewpoint - InMed Pharmaceuticals has been granted an international Patent Cooperation Treaty (PCT) patent for its proprietary small molecule drug candidates aimed at treating diseases with high unmet medical needs, including Alzheimer's disease and dry age-related macular degeneration [1][2][3] Patent Details - The patent titled "Cannabinoid analogs and methods for their preparation" protects several proprietary small molecule compounds and their preparation methods, with a 20-year term starting from its issuance in Mexico [2][5] - This patent strengthens InMed's intellectual property portfolio, ensuring protection for innovative cannabinoid analogs designed for various therapeutic applications, including neurological disorders and inflammation [2][3] - The PCT application is pending in several jurisdictions, including the U.S., Europe, and Japan, indicating a strategic approach to global patent protection [2][3] Company Overview - InMed Pharmaceuticals focuses on developing a pipeline of proprietary small molecule drug candidates targeting CB1/CB2 receptors, with programs in Alzheimer's, ocular, and dermatological indications [7] - The company has a total of 14 patent families covering compositions, formulations, manufacturing processes, and methods of use, highlighting its commitment to expanding its patent portfolio [3][4]
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds